<p>温哥华，不列颠哥伦比亚省 --（Newsfile Corp. -2025 年 12 月 17 日）- InMed Pharmaceuticals Inc.（纳斯达克：INM）（&#34; <strong>InMed</strong>&#34;或&#34; <strong>公司</strong>&#34;），是一家专注于开发针对高未满足医疗需求疾病的专有小分子药物候选者的制药公司，今天确认，在 2025 年 12 月 17 日举行的年度股东大会和特别股东会议（&#34; <strong>会议</strong>&#34;）上，股东们对 InMed 在 2025 年 11 月 3 日发布的会议通知和管理信息通函中提出的事项进行了投票。会议上，共有 993,491 股公司的普通股，约占公司已发行和流通的 2,804,186 股普通股的 35.43%，以亲自或委托代理的方式出席。</p>
<p>会议上董事会（&#34; <strong>董事会</strong>&#34;）选举的投票结果如下：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>董事</strong></td>
<td><strong>赞成票</strong></td>
<td><strong>弃权票</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>数量</strong></td>
<td><strong>百分比</strong></td>
<td><strong>数量</strong></td>
<td><strong>百分比</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Eric A. Adams</strong></td>
<td>125,352</td>
<td>82.03%</td>
<td>27,469</td>
<td>17.98%</td>
</tr>
<tr>
<td><strong>Andrew Hull</strong></td>
<td>125,315</td>
<td>82.00%</td>
<td>27,506</td>
<td>18.00%</td>
</tr>
<tr>
<td><strong>Nicole Lemerond</strong></td>
<td>125,485</td>
<td>82.11%</td>
<td>27,336</td>
<td>17.89%</td>
</tr>
<tr>
<td><strong>Neil Klompas</strong></td>
<td>125,444</td>
<td>82.09%</td>
<td>27,377</td>
<td>17.91%</td>
</tr>
<tr>
<td><strong>John Bathery</strong></td>
<td>125,227</td>
<td>81.94%</td>
<td>27,594</td>
<td>18.06%</td>
</tr>
</tbody>
</table>
<p>此外，股东们投票批准 CBIZ CPAs P.C.作为公司下一年的审计师。</p>
<p>股东们还投票批准根据与 YA II PN, Ltd.于 2025 年 6 月 13 日修订的备用股权购买协议，潜在发行 20% 或更多截至 2024 年 12 月 13 日公司已发行和流通的普通股，符合纳斯达克上市规则 5635(d) 和 5635(b)（&#34; <strong>SEPA</strong>&#34;）。</p>
<p>InMed 于 2025 年 12 月 17 日在 SEDAR+ 上提交了投票结果报告，网址为 www.sedarplus.ca。</p>
<p><strong>关于 InMed：</strong></p>
<p>InMed Pharmaceuticals 是一家专注于开发针对 CB1/CB2 受体的专有小分子药物候选者的制药公司。InMed 的产品线包括针对阿尔茨海默病、眼科和皮肤科适应症的三个独立项目。有关更多信息，请访问 www.inmedpharma.com。</p>
<p><strong>关于前瞻性信息的警示说明：</strong></p>
<p>本新闻稿及公司及其高管和董事的口头声明包含适用证券法意义上的&#34;前瞻性信息&#34;和&#34;前瞻性声明&#34;（统称为&#34;前瞻性信息&#34;）。前瞻性声明通常通过&#34;预计&#34;、&#34;预期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;潜在&#34;、&#34;可能&#34;、&#34;将&#34;及类似表达来识别。这些声明基于管理层当前的预期，固有地涉及许多已知和未知的风险、不确定性和假设，其中许多超出我们的控制。前瞻性信息基于管理层当前的期望和信念，并受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性声明中描述的结果有实质性差异。在不限制前述内容的情况下，前瞻性信息包括但不限于关于 H.R. 5371，即&#34;2026 年持续拨款、农业、立法部门、军事建设和退伍军人事务及扩展法案&#34;（&#34; <strong>法案</strong>&#34;）的声明，法案对 BayMedica Inc.的影响，法案的任何潜在修改及/或其时机，以及 BayMedica 和公司的可选方案，关于开发针对高未满足医疗需求疾病的专有小分子药物候选者的声明，以及关于根据 SEPA 潜在发行普通股的声明。</p>
<p>此外，存在已知和未知的风险因素，可能导致 InMed 的实际结果、表现或成就与前瞻性信息中表达或暗示的任何未来结果、表现或成就有实质性差异。InMed 的年度报告（10-K 表格）及其季度报告（10-Q 表格）、当前报告（8-K 表格）以及向证券交易委员会提交或提供的任何其他文件中披露了 InMed 业务面临的风险和不确定性。</p>
<p>本文件中的所有前瞻性信息均受到本警示声明的完全限制，InMed 不承担修订或更新任何此类前瞻性信息的义务，也不承担公开宣布任何修订结果以反映未来结果、事件或发展的义务，除非法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/278446_a7fda5c4c43f1b03_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/278446_a7fda5c4c43f1b03_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/278446</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/278446/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/278446/375"/></p>

<p>InMed Pharmaceuticals Inc. 宣布了其 2025 年年度股东大会和特别会议的结果。股东们对多个事项进行了投票，包括董事会的选举和批准 CBIZ CPAs P.C. 作为审计师。他们还批准了根据备用股权购买协议可能发行 20% 或更多公司普通股的提案。约 35.43% 的公司股份在会议上得到了代表。InMed 专注于开发针对高未满足需求疾病的小分子药物候选者</p>

<p>Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (&#34; <strong>InMed</strong>&#34; or the &#34; <strong>Company</strong>&#34;), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders held on December 17, 2025 (the &#34; <strong>Meeting</strong>&#34;), the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated November 3, 2025, were voted upon by the shareholders. A total of 993,491 common shares of the Company, representing approximately 35.43% of the Company's 2,804,186 issued and outstanding common shares, were represented in person or by proxy at the Meeting.</p>
<div class="lb-trans"><p>温哥华，不列颠哥伦比亚省 --（Newsfile Corp. -2025 年 12 月 17 日）- InMed Pharmaceuticals Inc.（纳斯达克：INM）（&#34; <strong>InMed</strong>&#34;或&#34; <strong>公司</strong>&#34;），是一家专注于开发针对高未满足医疗需求疾病的专有小分子药物候选者的制药公司，今天确认，在 2025 年 12 月 17 日举行的年度股东大会和特别股东会议（&#34; <strong>会议</strong>&#34;）上，股东们对 InMed 在 2025 年 11 月 3 日发布的会议通知和管理信息通函中提出的事项进行了投票。会议上，共有 993,491 股公司的普通股，约占公司已发行和流通的 2,804,186 股普通股的 35.43%，以亲自或委托代理的方式出席。</p>
</div><p>Results of the vote for the election of the board of directors (the &#34; <strong>Board</strong>&#34;) at the Meeting are set out as follows:</p>
<div class="lb-trans"><p>会议上董事会（&#34; <strong>董事会</strong>&#34;）选举的投票结果如下：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Director</strong></td>
<td><strong>Votes For</strong></td>
<td><strong>Withheld Votes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Number</strong></td>
<td><strong>Percentage</strong></td>
<td><strong>Number</strong></td>
<td><strong>Percentage</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Eric A. Adams</strong></td>
<td>125,352</td>
<td>82.03%</td>
<td>27,469</td>
<td>17.98%</td>
</tr>
<tr>
<td><strong>Andrew Hull</strong></td>
<td>125,315</td>
<td>82.00%</td>
<td>27,506</td>
<td>18.00%</td>
</tr>
<tr>
<td><strong>Nicole Lemerond</strong></td>
<td>125,485</td>
<td>82.11%</td>
<td>27,336</td>
<td>17.89%</td>
</tr>
<tr>
<td><strong>Neil Klompas</strong></td>
<td>125,444</td>
<td>82.09%</td>
<td>27,377</td>
<td>17.91%</td>
</tr>
<tr>
<td><strong>John Bathery</strong></td>
<td>125,227</td>
<td>81.94%</td>
<td>27,594</td>
<td>18.06%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>董事</strong></td>
<td><strong>赞成票</strong></td>
<td><strong>弃权票</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>数量</strong></td>
<td><strong>百分比</strong></td>
<td><strong>数量</strong></td>
<td><strong>百分比</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Eric A. Adams</strong></td>
<td>125,352</td>
<td>82.03%</td>
<td>27,469</td>
<td>17.98%</td>
</tr>
<tr>
<td><strong>Andrew Hull</strong></td>
<td>125,315</td>
<td>82.00%</td>
<td>27,506</td>
<td>18.00%</td>
</tr>
<tr>
<td><strong>Nicole Lemerond</strong></td>
<td>125,485</td>
<td>82.11%</td>
<td>27,336</td>
<td>17.89%</td>
</tr>
<tr>
<td><strong>Neil Klompas</strong></td>
<td>125,444</td>
<td>82.09%</td>
<td>27,377</td>
<td>17.91%</td>
</tr>
<tr>
<td><strong>John Bathery</strong></td>
<td>125,227</td>
<td>81.94%</td>
<td>27,594</td>
<td>18.06%</td>
</tr>
</tbody>
</table>
</div><p>In addition, shareholders voted to approve CBIZ CPAs P.C. as the Company's auditors for the following year.</p>
<div class="lb-trans"><p>此外，股东们投票批准 CBIZ CPAs P.C.作为公司下一年的审计师。</p>
</div><p>Shareholders also voted to approve the potential issuance of 20% or more of the Company's common shares issued and outstanding as of December 13, 2024, pursuant to the Standby Equity Purchase Agreement with YA II PN, Ltd., as amended on June 13, 2025, pursuant to Nasdaq Listing Rules 5635(d) and 5635(b) (the &#34; <strong>SEPA</strong>&#34;).</p>
<div class="lb-trans"><p>股东们还投票批准根据与 YA II PN, Ltd.于 2025 年 6 月 13 日修订的备用股权购买协议，潜在发行 20% 或更多截至 2024 年 12 月 13 日公司已发行和流通的普通股，符合纳斯达克上市规则 5635(d) 和 5635(b)（&#34; <strong>SEPA</strong>&#34;）。</p>
</div><p>InMed filed a report of voting results on SEDAR+ at www.sedarplus.ca on December 17, 2025.</p>
<div class="lb-trans"><p>InMed 于 2025 年 12 月 17 日在 SEDAR+ 上提交了投票结果报告，网址为 www.sedarplus.ca。</p>
</div><p><strong>About InMed:</strong></p>
<div class="lb-trans"><p><strong>关于 InMed：</strong></p>
</div><p>InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.</p>
<div class="lb-trans"><p>InMed Pharmaceuticals 是一家专注于开发针对 CB1/CB2 受体的专有小分子药物候选者的制药公司。InMed 的产品线包括针对阿尔茨海默病、眼科和皮肤科适应症的三个独立项目。有关更多信息，请访问 www.inmedpharma.com。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Information:</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性信息的警示说明：</strong></p>
</div><p>This news release, and oral statements by the Company and its executive officers and directors, contain &#34;forward-looking information&#34; and &#34;forward-looking statements&#34; (collectively, &#34;forward-looking information&#34;) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as &#34;expects&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;potential&#34;, &#34;possible&#34;, &#34;would&#34; and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information includes, but is not limited to, statements about H.R. 5371, the &#34;Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026&#34; (the &#34; <strong>Act</strong>&#34;), the impact of the Act on BayMedica Inc., any potential modifications to the Act and/or the timing thereof and the alternative options available to BayMedica and the Company, statements about developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, and statements about the potential issuance of common shares pursuant to the SEPA.</p>
<div class="lb-trans"><p>本新闻稿及公司及其高管和董事的口头声明包含适用证券法意义上的&#34;前瞻性信息&#34;和&#34;前瞻性声明&#34;（统称为&#34;前瞻性信息&#34;）。前瞻性声明通常通过&#34;预计&#34;、&#34;预期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;潜在&#34;、&#34;可能&#34;、&#34;将&#34;及类似表达来识别。这些声明基于管理层当前的预期，固有地涉及许多已知和未知的风险、不确定性和假设，其中许多超出我们的控制。前瞻性信息基于管理层当前的期望和信念，并受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性声明中描述的结果有实质性差异。在不限制前述内容的情况下，前瞻性信息包括但不限于关于 H.R. 5371，即&#34;2026 年持续拨款、农业、立法部门、军事建设和退伍军人事务及扩展法案&#34;（&#34; <strong>法案</strong>&#34;）的声明，法案对 BayMedica Inc.的影响，法案的任何潜在修改及/或其时机，以及 BayMedica 和公司的可选方案，关于开发针对高未满足医疗需求疾病的专有小分子药物候选者的声明，以及关于根据 SEPA 潜在发行普通股的声明。</p>
</div><p>Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's business is disclosed in InMed's Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any other documents filed or furnished with the Securities and Exchange Commission available on www.sec.gov.</p>
<div class="lb-trans"><p>此外，存在已知和未知的风险因素，可能导致 InMed 的实际结果、表现或成就与前瞻性信息中表达或暗示的任何未来结果、表现或成就有实质性差异。InMed 的年度报告（10-K 表格）及其季度报告（10-Q 表格）、当前报告（8-K 表格）以及向证券交易委员会提交或提供的任何其他文件中披露了 InMed 业务面临的风险和不确定性。</p>
</div><p>All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.</p>
<div class="lb-trans"><p>本文件中的所有前瞻性信息均受到本警示声明的完全限制，InMed 不承担修订或更新任何此类前瞻性信息的义务，也不承担公开宣布任何修订结果以反映未来结果、事件或发展的义务，除非法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/278446_a7fda5c4c43f1b03_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/9540/278446_a7fda5c4c43f1b03_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278446</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/278446</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/278446/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/278446/375"/></p>

InMed 宣布 2025 年度股东大会及特别会议结果 | INM 股票新闻